Keybank National Association OH Grows Stake in Cencora, Inc. $COR

Keybank National Association OH increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 21.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,702 shares of the company’s stock after purchasing an additional 3,159 shares during the quarter. Keybank National Association OH’s holdings in Cencora were worth $5,561,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Twin City Private Wealth LLC raised its holdings in Cencora by 3.8% during the first quarter. Twin City Private Wealth LLC now owns 2,549 shares of the company’s stock worth $801,000 after purchasing an additional 93 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in shares of Cencora by 4.2% in the 1st quarter. Essex Financial Services Inc. now owns 1,310 shares of the company’s stock valued at $411,000 after buying an additional 53 shares in the last quarter. Fulton Bank N.A. grew its position in shares of Cencora by 13.2% in the 1st quarter. Fulton Bank N.A. now owns 6,160 shares of the company’s stock valued at $1,935,000 after buying an additional 719 shares during the last quarter. Vertrix Wealth Management LLC acquired a new stake in Cencora during the 1st quarter worth $920,000. Finally, USS Investment Management Ltd raised its stake in Cencora by 3.5% during the 1st quarter. USS Investment Management Ltd now owns 31,587 shares of the company’s stock worth $9,922,000 after acquiring an additional 1,065 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Down 0.0%

Shares of NYSE:COR opened at $296.43 on Friday. The stock has a market cap of $57.67 billion, a P/E ratio of 22.73, a P/E/G ratio of 1.65 and a beta of 0.58. The firm has a fifty day moving average price of $277.91 and a 200 day moving average price of $320.37. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the prior year, the firm posted $4.42 earnings per share. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has authorized a stock buyback program on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Insider Buying and Selling

In related news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction on Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.38% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Barclays cut their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. Robert W. Baird reduced their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Wells Fargo & Company decreased their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average price target of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.